Physician profile
Sabu John
NPI 1386611531
$6,563.19
in general payments reported to CMS, 2019-2025
26 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,253 · 2020: $464 · 2021: $345 · 2022: $620 · 2023: $1,457 · 2024: $553 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475 · Travel and Lodging: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.36 |
| Travel and Lodging | $406.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $1,747.00 | 2019 | |
| Medtronic, INC. | $876.37 | 2022-2023 | Corevalve Evolut R, Cg Future |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $545.18 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $450.51 | 2022-2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $442.10 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $420.68 | 2019-2025 | Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $411.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $341.26 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $217.17 | 2022-2025 | Verquvo |
| Pfizer INC. | $183.08 | 2021-2024 | |
| Nuwellis, INC. | $121.99 | 2020 | |
| Abbott Laboratories | $118.07 | 2019-2025 | Ensite Precision, Cardiomems |
| Irhythm Technologies, INC. | $116.36 | 2024 | Zio Monitor, Zio Xt Patch |
| Scpharmaceuticals INC. | $86.75 | 2024-2025 | |
| Bridgebio Pharma, INC. | $80.98 | 2025 | Attruby |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $60.28 | 2020-2023 | Renamic Neo |
| Amgen INC. | $59.74 | 2022 | |
| Acarix USA INC. | $52.64 | 2022 | |
| Boston Scientific Corporation | $50.64 | 2019-2022 | |
| Edwards Lifesciences Corporation | $40.73 | 2025 | Sapien 3 Ultra Resilia |
| Lexicon Pharmaceuticals, INC. | $35.05 | 2023 | Inpefa |
| Philips North America LLC | $32.66 | 2025 | Ecc Solutions |
| Bracco Diagnostics INC. | $23.31 | 2025 | |
| Lilly USA, LLC | $20.36 | 2023 | Mounjaro |
| Medtronic Vascular, INC. | $14.85 | 2019 | |
| Astellas Pharma US INC | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabu John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.